Ocular Therapeutix to Present Key Data at July Retina Conferences
Event summary
- Ocular Therapeutix will present at three scientific and investor conferences in July 2026.
- Key presentations include Phase 3 trial results for AXPAXLI (OTX-TKI) in wet AMD on July 16, 2026.
- CEO Pravin U. Dugel to participate in a fireside chat at HC Wainwright conference on July 22, 2026.
The big picture
Ocular Therapeutix is positioning itself as a key player in retina therapeutics with its ELUTYX technology platform. The company's focus on durable therapies for wet AMD and diabetic retinal disease comes amid increasing competition in the ophthalmology space, particularly around anti-VEGF alternatives.
What we're watching
- Clinical Data Impact
- How Phase 3 SOL-1 trial results for AXPAXLI will position Ocular Therapeutix in the wet AMD market.
- Regulatory Pathway
- Whether recent FDA guidance discussed at OIS Retina will affect OTX-TKI's development timeline.
- Investor Sentiment
- The reception of CEO Pravin U. Dugel's strategic vision during the HC Wainwright fireside chat.
Related topics